secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0001437749-25-021978
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic rebrands as Dyadic Applied BioSolutions; highlights $250K milestone & $1.5M Gates grant
--------------------------------------------------------------------------------

- Will do business as Dyadic Applied BioSolutions effective in 30 days; legal name unchanged.
- Reports $250,000 milestone payment for second non-animal dairy enzyme program.
- Received second $1.5M installment from $3.0M Gates Foundation grant for malaria/RSV mAbs.
- Company shifts from research-driven to commercially focused enterprise on non-therapeutic proteins.
- Targets commercialization of input proteins in 2025; C1 and Dapibus platforms are core.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774925021978/0001437749-25-021978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774925021978/dyai20250702_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-021978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer